Purpose: Recently, laparoscopy-assisted gastrectomy (LAG) has been widely accepted modality for early gastric cancer in Korea. The indication of LAG may be extended in an experienced institution. In our institution, the first case of laparoscopy-assisted gastrectomy (LAG) for gastric cancer was performed in May 1998. We retrospectively reviewed the long-term oncologic outcomes over 12 years to clarify the feasibility of LAG for gastric cancer. Materials and Methods: The authors retrospectively analyzed 753 patients who underwent LAG for gastric cancer, from May 1998 to August 2010. We reviewed clinicopathological features, postoperative outcomes, mortality and morbidity, recurrence, and survival of LAG for gastric cancer. Results: During the time period, 3,039 operations for gastric cancer were performed. Among them, 753 cases were done by LAG (24.8%). There were 69 cases of total gastrectomy, 682 subtotal gastrectomies, and 2 proximal gastrectomies. According to TNM stage, 8 patients were in stage 0, 619 in stage I, 88 in stage II, and 38 in stage III. The operation-related complications occurred in 77 cases (10.2%). Median follow-up period was 56.2 months (range 0.7~165.6 months). Twenty-five patients (3.3%) developed recurrence, during the follow-up period. The overall 5-year and disease free survival rates were 97.1% and 96.3%, respectively. Conclusions: The number of postoperative complications and survival rates of our series were comparable to the results from that of other reports. The authors consider LAG to be a feasible alternative for the treatment of early gastric cancer. However, rationale for laparoscopic surgery in advanced gastric cancer has yet to be determined.
Introduction
Surgical resection for gastric cancer is the only therapeutic modality for curability.(1) Laparoscopy-assisted gastrectomy (LAG) has been applied and increased significantly in the surgical management of gastric cancer in recent years. In Asian countries, such as Japan and Korea, it has become a standard therapy for early stage gastric cancer. (2, 3) Several studies have demonstrated short-term postoperative advantages of LAG.(3-5) Kitano et al. (2) reported excellent long-term outcome of laparoscopic gastrectomy in a retrospective multicenter study for early gastric cancer.
Recently, there was first multicenter, prospective, randomized trial for laparoscopy-assisted distal gastrectomy to assess the short-and long-term outcomes for early gastric cancer in Korea (Korea Laparoscopic Gastrointestinal Surgery Study Group [KLASS] trial). (6) In the near future, this trial will prove that laparoscopic surgery is feasible and acceptable procedure and will hopefully answer the concern of long term outcomes. Furthermore, improvements in instruments and laparoscopic technique have allowed for widespread acceptance of laparoscopic surgery, not only for distal gastrectomy but also for other gastrectomy.(7-9) As a results, study is needed to confirm that this procedure is oncologically feasible from a longterm follow-up perspective.
Since 1998, 753 cases of LAG have been performed at our institution by two surgeons. Based on these data of our 12 year experience, we have reviewed the oncological outcomes for laparoscopyassisted gastrectomy, to determine its long-term effectiveness and patient survival.
Materials and Methods
Between May 1998 and August 2010, 3,039 operations for gastric cancer were performed in our institute. Among them, 753 patients underwent LAG by two experienced surgeons. We assessed the depth of invasion preoperatively by means of endoscopy and endoscopic ultrasonography and assessed the presence or absence of lymph node metastases using computed tomography. In early periods, our indication of LAG for gastric cancer was cT1N0M0 according to the 6th edition of the American Joint Committee on All patients were managed routinely using a standardized postoperative protocol as follows: (1) no nasogastric intubation or preoperative mechanical bowel preparation, (2) minimal spillage of gastric contents, (3) the use of one or two closed suction drains, (4) sips of water at 48 hours after the operation, (5) a clear liquid diet at three days after the operation, and (6) discharge at six or seven days after a soft diet with no abnormal clinical symptoms. In advanced gastric cancer cases with stages beyond stage II, they received six cycles of adjuvant chemotherapy with intravenous 5-fluorouracil and cisplatin.
Follow-up results were obtained from patient hospital records, and telephone calls, and recurrence was determined by endoscopy, computed tomography, and positron emission tomography. All the follow-up patients were monitored postoperatively by a routine check for blood tests, tumor marker (Alpha-Fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9), chest radiography, endoscopy, and computed tomography. In patients with early gastric cancer, follow-up studies were performed every six months for the second year and annually for the following years.
For patients with advanced gastric cancer, studies were carried out every three months for the first year, every six months for next year, and annually for the next three years.
Statistical results of the clinicopathologic factors and postoperative outcomes were analyzed using GraphPadInStat ® (version 3.06, GraphPad Software Inc., San Diego, CA, USA). Survival curves were calculated by the Kaplan-Meier method using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Surgical procedure
All laparoscopy-assisted gastrectomies were performed according to the standard procedure guidelines as follows. All patients 
Results

Patient characteristics
Since May 1998, laparoscopy-assisted gastrectomies have gradually increased in our institute (Fig. 1 ). The clinicopathological characteristics ofthe patients are presented in Table 1 (Table 1) .
Postoperative outcomes
For all 753 patients, the meanoperation time was 214.0±52.6 min (range, 110~415 min; partial gastrectomy, 209.3±49.9 min; Partial gastrectomy includes distal subtotal gastrectomy and proximal subtotal gastrectomy. LAG = laparoscopy-assisted gastrectomy. 
Follow-up results
The median follow-up period was 56.2 months (range 0.7~165.6 months). Tumor recurrence was detected in 25 patients (3.3%)
during the follow-up period. The sites of recurrence are shown in Table 4 . Twenty-five patients had a total of 34 specific sites of recurrence. Hepatic and lymph node metastasis were the most common specific sites of recurrence. As for lymph node metastases, one patient was found at para-aortic area, 2 at extra-abdominal area, 1 at peripancreatic area, 1 at pericholedochal area, and 1 at perigastric area.
The overall 5-year survival rate and disease free survival rate were 97.1% and 96.3%, respectively (Fig. 2) . According to TNM stage, the overall 5-year and disease-free survival rates were 100% (Fig. 3) . currence following LAG for gastric cancer. They stated that the incidence of recurrence was 3.5% in all patients, 1.6% in early gastric cancer, and 13.4% in advanced gastric cancer. During our followup period, we detected 25 patients (3.3%) with tumor recurrence.
Incidence of recurrence was 1.4% (8/592) in early gastric cancer and 10.6% (17/161) in advanced gastric cancer. Tokunaga et al. (27) said that patients with clinically early but pathologically advanced gastric cancer had a better prognosis compared to patients with clinically and pathologically advanced gastric cancer. As a result, we could explain the lower rate of recurrence of advanced gastric cancer in our LAG cases because of the reason mentioned above.
In terms of the specific recurrence site, Song et al. (26) reported that the peritoneum and liver were the most common recurrence sites. Also, Lee and Kim(28) said that the peritoneum and liver were major sites of recurrence. In the present study, liver (8 sites), peritoneal metastasis (6 sites), and lymph node metastasis (9 sites)
were the most common specific sites of recurrence. Some authors reported their period of recurrence after operation. Song et al. (26) showed that recurrences mostly occurred within three years.
Hwang et al. (29) reported that their recurrences occurred within 34 months. In the same manner, most recurrences (21/25) in our study occurred within three years. Although further study is needed comparing LAG to open gastrectomy, we think that LAG with adequate lymph node dissection for early gastric cancer is an oncologically safe, feasible, and curative procedure. However, rationale for laparoscopic surgery in advanced gastric cancer has yet to be determined. Therefore, a large-scale multicenter randomized trial is needed to confirm the oncological safety and feasibility of LAG for patients with advanced gastric cancer.
